Longitudinal Outbreak of Multidrug-Resistant Tuberculosis in a Hospital Setting, Serbia

Irena Arandjelović,1 Matthias Merker,¹ Elvira Richter, Thomas A. Kohl, Branislava Savić, Ivan Soldatović, Thierry Wirth, Dragana Vuković,¹ Stefan Niemann¹

A retrospective population-based molecular epidemiologic study of multidrug-resistant Mycobacterium tuberculosis complex strains in Serbia (2008–2014) revealed an outbreak of TUR genotype strains in a psychiatric hospital starting around 1990. Drug unavailability, poor infection control, and schizophrenia likely fueled acquisition of additional resistance and bacterial fitness–related mutations over 2 decades.

The overall burden of tuberculosis (TB) in Serbia has been greatly reduced in recent years (1,2). However, a recent study revealed transmission of multidrug-resistant (MDR) Mycobacterium tuberculosis complex (MTBC) strains (i.e., MTBC strains resistant to at least rifampin and isoniazid) in Belgrade (3). In addition, data retrieved from the national database of MDR TB patients indicate a concentrated burden of MDR TB and extensively drug-resistant (XDR) TB, defined as additional resistance to 1 fluoroquinolone and 1 of the 3 injectable second-line drugs, among psychiatric in-patients in Serbia. To gain more insights into countrywide transmission routes, strain dynamics, and bacterial evolution over time, we retrospectively investigated all (n = 110) patients who received a diagnosis of MDR TB during January 1, 2008–May 31, 2014, in Serbia.

The Study

We subjected 1 MTBC isolate per patient to phenotypic drug susceptibility testing and whole-genome sequencing (WGS) (Appendix 1, https://wwwnc.cdc.gov/EID/article/25/3/18-1220-App1.pdf). We retrieved patients’ demographic, epidemiologic, and clinical data from the national database of MDR TB patients, as well as from their medical and laboratory records.

Most patients were male (87/110, 79.1%) and born in Serbia (107/110, 97.3%); mean age was 49.5 years (range 15–83). We observed concurrent conditions for 55 patients; schizophrenia was the most prevalent (26/55, 47.3%). Of the 110 patients, 61 (55.5%) had previously experienced TB. Susceptibility testing results showed that 19/110 (17.3%) MDR MTBC isolates were resistant to all first-line drugs, and 11/110 (10.0%) were classified as XDR (Appendix 1 Table 1). We successfully completed WGS for 103/110 isolates, representing 93.6% of all MDR TB cases recorded over the study period.

We considered 6,512 single-nucleotide polymorphisms (SNPs) differentiating all isolates to analyze their phylogenetic relationships. The MDR MTBC strain population comprised 37/103 (35.9%) isolates classified as lineage 4.2.2.1 (TUR genotype), 20/103 (19.4%) isolates of lineage 4.1.2 (Haarlem genotype), 17/103 (16.5%) isolates of lineage 2.2.1 (Beijing genotype), 15/103 (14.6%) isolates of lineage 4.8 (H37Rv-like strains), 8/103 (7.8%) isolates of lineage 4.4.1.1 (S-type), 2/103 (1.9%) isolates of lineage 4.2.1 (URAL genotype), 1 isolate of lineage 4.1 (Ghana), and 1 nonclassified lineage 4 isolate. Among lineage 2.2.1 Beijing isolates, the previously described Europe/Russia W148 MDR outbreak isolates (4) were most prevalent, present in 14/17 (82.4%) of the cases (Figure 1; Appendix 2, https://wwwnc.cdc.gov/EID/article/25/3/18-1220-App2.xls).

Seeking to identify recent chains of transmission, we defined molecular clusters as surrogate markers for epidemiologically linked cases (Appendix 1). Overall, 63/103 (61.2%) isolates could be assigned to 12 different clusters, each including 2–17 patients. The 2 largest clusters, 1 containing 14 and 1 containing 17 cases, comprised isolates of TUR genotype; the next-largest cluster was of 7 Beijing Europe/Russia W148 isolates. For all 63 suggested epidemiologic links, we were able to retrospectively identify 40 (63.5%) epidemiologic links (e.g., household and social contacts) (Appendix 1 Figure 1).

Our main finding was that 35/37 (94.6%) TUR isolates shared identical mutations that confer drug resistance to isoniazid (katG S315T), streptomycin (rpsL K43R), and ethambutol (embB Q497R); we therefore classified them as TUR-outbreak isolates. TUR-outbreak isolates further differentiated into 2 individual transmission chains characterized...
by 2 distinct rifampin resistance–mediating mutations: \textit{rpoB} S450W in 1998 (95% highest posterior density [HPD] 1993–2001) and \textit{rpoB} S450L in 2003 (95% HPD 2000–2005) (Figure 2, panel A; Appendix 1 Figure 2). Subsequently, both strain populations acquired individual mutations in other RNA polymerase genes (\textit{rpoA} P25R, \textit{rpoC} V431M, and \textit{rpoC} F452L), which have been proposed to enhance the in vitro growth rate of rifampin-resistant strains (7). Furthermore, \textit{rpoA} mutations in the entire dataset were more likely to arise in clustered isolates than in unique isolates (20/63 vs. 1/40; p<0.001), thus indicating their ability to restore fitness of \textit{rpoB} mutants, increase transmission success, or both.

Of the 35 TUR-outbreak isolates, 26 (74.3%) were from patients hospitalized in Bela Crkva (BC) Hospital, the national center for treatment of all psychiatric patients with concomitant respiratory illnesses. Of note, 22 (84.6%) of these 26 patients had been transferred from 7 different psychiatric hospitals to BC Hospital for pulmonary diagnosis and treatment; 5 were admitted at BC Hospital with either confirmed or suspected TB diagnosis (Appendix 2). Screening for TB at time of admission had not been implemented in BC Hospital during the study period.

To determine the geographic origin of the 3-fold resistant TUR ancestor and to test for the putative independent introduction of 2 different rifampin-resistant cases to the BC Hospital from other hospitals, we extended our Bayesian approach with a discrete trait model introducing the likely place of infection for each patient. We used 2 assumptions: first, a fast disease progression assumed infection and diagnosis of MDR TB within the first 2 years after admission to BC Hospital; and second, a slow disease progression in which patients who received a diagnosis within 2 years after admission were identified as latent MDR TB cases, meaning they had contracted the infection in their hometown or a previous hospital.

The comparison of both models using path sampling clearly favored the fast progression model, suggesting the origin of the TUR outbreak in BC Hospital with a probability of 53% (i.e., node location probability; second likely origin was Belgrade, 12%) (Figure 2, panel A). The 2 unique rifampin-resistance mediating mutations were also more likely to have originated in BC Hospital itself (51% for \textit{rpoB} S540W node, 95% for \textit{rpoB} S540L node, and <15% for other location probabilities). Individual transmission events occurred in remote cities but also within Belgrade (Figure 2, panels A, B). In comparison, applying the slow TB progression hypothesis, TUR outbreak strains would have been imported multiple times from different regions throughout the country to BC Hospital, with node location probabilities <10% for all locations (Appendix 1 Figure 3). Tracing the time of hospitalization at BC Hospital and MDR TB diagnosis of patients infected with TUR strains backward revealed that the 2 clades (defined by \textit{rpoB} S450L and \textit{rpoB} S450W) indeed coexisted over 2 decades (Appendix 1 Figure 4).
Conclusions

In a retrospective approach using WGS-based molecular epidemiology, Bayesian statistics, and detailed epidemiologic investigations, we show that MDR TB in Serbia is associated with nosocomial transmission at BC Hospital, likely accompanied by a fast progression to disease within 2 years. Drug unavailability in the 1990s, schizophrenia as a recognized cause of unsuccessful completion of TB treatment, and long-term and repeated hospitalizations under extremely adverse living conditions, together with the absence of a TB infection control program, are believed to be the main drivers of the evolutionary trajectories and success of TUR-outbreak strains in Serbia. The TUR-outbreak strain was considered intrinsically resistant to 3 first-line drugs and probably acquired an MDR genotype in 2 independent events in BC Hospital during the 1990s. Subsequently, putative compensatory mechanisms were selected, the strain acquired individual XDR genotypes, and it spread into other settings in Serbia by family contacts and other modes.

Detection of the extensive transmission network in BC Hospital led to the development and implementation of an appropriate TB infection control program featuring the use of rapid laboratory tests for prompt detection of new cases, completion of appropriate second-line treatment regimens, and markedly expanded contact tracing activities. Since 2015, only 1 new case of MDR TB has been recorded in BC Hospital. However, MDR TB transmission in the general population must continue to be carefully monitored.

Figure 2. Most likely temporal and spatial origin of Mycobacterium tuberculosis complex (MTBC) TUR genotype outbreak strains in Serbia. A) Location annotated time-scaled phylogeny (maximum clade credibility tree) derived from a Bayesian discrete trait phylogeographical analysis of 37 lineage 4.2.2.1 (TUR genotype) multidrug-resistant (MDR) MTBC isolates. Branches are color-coded according to the most likely place of infection, assuming a fast-progression hypothesis (Appendix 1, https://wwwnc.cdc.gov/EID/article/25/3/18-1220-App1.pdf). Branches are annotated with location probabilities; symbols represent acquisition of individual resistance-related mutations shared by all derived strains. B) Regional and countrywide spread of individual TUR genotype outbreak strains originating from Bela Crkva Hospital. Arrows indicate inferred location changes determined from the genealogy shown in panel A.

Conclusions

In a retrospective approach using WGS-based molecular epidemiology, Bayesian statistics, and detailed epidemiologic investigations, we show that MDR TB in Serbia is associated with nosocomial transmission at BC Hospital, likely accompanied by a fast progression to disease within 2 years. Drug unavailability in the 1990s, schizophrenia as a recognized cause of unsuccessful completion of TB treatment, and long-term and repeated hospitalizations under extremely adverse living conditions, together with the absence of a TB infection control program, are believed to be the main drivers of the evolutionary trajectories and success of TUR-outbreak strains in Serbia. The TUR-outbreak strain was considered intrinsically resistant to 3 first-line drugs and probably acquired an MDR genotype in 2 independent events in BC Hospital during the 1990s. Subsequently, putative compensatory mechanisms were selected, the strain acquired individual XDR genotypes, and it spread into other settings in Serbia by family contacts and other modes.

Detection of the extensive transmission network in BC Hospital led to the development and implementation of an appropriate TB infection control program featuring the use of rapid laboratory tests for prompt detection of new cases, completion of appropriate second-line treatment regimens, and markedly expanded contact tracing activities. Since 2015, only 1 new case of MDR TB has been recorded in BC Hospital. However, MDR TB transmission in the general population must continue to be carefully monitored.
Acknowledgments
We thank J. Zallet, I. Razio, and V. Mohr for excellent support in library preparation and whole-genome sequencing. We thank R. Ćurčić for her help in retrieving data from the Serbian National Database of MDR TB patients, and Lj. Ušan-Miličković for providing data on patients hospitalized in Bela Crkva Hospital. We gratefully acknowledge the Serbian Laboratory Network for tuberculosis and the Supranational Reference Laboratory for Tuberculosis, Forschungszentrum Borstel, Borstel, Germany, for contributions to the study.

About the Author
Dr. Arandjelović is a teaching assistant in the Department of Microbiology, Faculty of Medicine, University of Belgrade, Belgrade. Her primary research interests are mycobacteriology, drug resistance, and molecular epidemiology of tuberculosis.

References
1. World Health Organization. Global tuberculosis report. Contract no.: WHO/HTM/TB/2017.23. Geneva: The Organization; 2017.
2. European Centre for Disease Prevention and Control; WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2017. Stockholm: European Centre for Disease Prevention and Control; 2017.
3. Vuković D, Rüsch-Gerdes S, Savić B, Niemann S. Molecular epidemiology of pulmonary tuberculosis in Belgrade, central Serbia. J Clin Microbiol. 2003;41:4372–7. http://dx.doi.org/10.1128/JCM.41.9.4372-4377.2003
4. Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet. 2015;47:242–9. http://dx.doi.org/10.1038/ng.3195
5. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812. http://dx.doi.org/10.1038/ncomms5812
6. Niemann S, Merker M, Kohl T, Supply P. Impact of genetic diversity on the biology of Mycobacterium tuberculosis complex strains. Microbiol Spectr. 2016;4:TBTB2-0022-2016.
7. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2012;44:106–10. http://dx.doi.org/10.1038/ng.1038
8. Jovanovic D, Skodric-Trifunovic V, Markovic-Denic L, Stevic R, Vlajinac H. Clinical and epidemiological evaluation of tuberculosis in Serbia, 1990–2004. Int J Tuberc Lung Dis. 2007;11:647–51.
9. Pachi A, Bratis D, Moussas G, Tselitis A. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberc Res Treat. 2013;2013:489865. http://dx.doi.org/10.1155/2013/489865
10. Tosevski DL, Gagic SD, Milovancevic MP. Mental healthcare in Serbia. Int Psychiatry. 2010;7:13–5. http://dx.doi.org/10.1192/S174367600000941

Address for correspondence: Irena Arandjelović, University of Belgrade Institute of Microbiology and Immunology, Faculty of Medicine, dr Subotica 1, 11000 Belgrade, Serbia; email: irena.arandjelovic@med.bg.ac.rs
Longitudinal Outbreak of Multidrug-Resistant Tuberculosis in a Hospital Setting, Serbia

Appendix 1

Materials and Methods

Bacterial Strains and Drug Susceptibility Testing (DST)

One isolate per patient was included in the study. The isolates were stored in glycerol stocks at −70°C, and re-cultured on Löwenstein-Jensen (LJ) media for 4–6 weeks at 37°C before further testing. Identification of the isolates was verified by the GenoType MTBC assay (Hain Lifescience, https://www.hain-lifescience.de/en/). DST for first- (except pyrazinamide (PZA)) and second-line drugs was performed with the indirect proportion method on LJ slants using World Health Organization (WHO) recommended critical concentrations during 2008–2011, and as described previously (1). PZA was tested in MGIT960 according to the manufacturer instructions and at WHO recommended critical concentrations. From 2012 onward, all drugs, except cycloserine (CS) and para-aminosalicylic acid (PAS), were tested in MGIT960. Both CS and PAS were still tested on LJ slants at 30 mg/L, and 1 mg/L with the indirect proportion method as recommended that time.

DNA Extraction

DNA extraction was performed by using QIAamp DNA Mini Kit (QIAGEN, http://www.qiagen.com) according to the manufacturer’s instructions. Briefly, one loop of bacterial colonies grown on LJ medium was suspended in 0.2 mL of the tissue lysis buffer with vortexing. Suspension was centrifuged for 10 min at 7,500 rpm. Bacterial pellet was resuspended in 180 μL of the appropriate enzyme solution (20 mg/ml lysozyme; 20 mM Tris-HCl, pH 8.0; 2 mM EDTA; 1.2% Triton), and incubated for 3h at 37°C. Twenty μLof Proteinase K and 200 μL of lysis buffer were added in each tube with vortexing, and all tubes were incubated at 56°C for
30 min, and then for a further 15 min at 95°C. After centrifugation, DNA extraction was completed following the manufacturer’s tissue protocol (from step 4).

**Whole-Genome Sequencing (WGS)**

DNA library preparation was performed according to the Nextera XT manufacturer instructions (Illumina, http://www.illumina.com). Sequencing was carried out with the Illumina MiSeq and HiSeq system with a minimum average coverage depth of 50-fold. Fastq files have been submitted to the European Nucleotide Archive (ENA); accession numbers are given in Appendix 2. Resulting reads were mapped to the *M. tuberculosis* H37Rv genome (GenBank accession no. NC_000962.3) using BWA-MEM (2), and mappings refined with the GATK software package (3).

Variants were detected with Samtools (4) and filtered with perl scripts for thresholds of a minimum coverage of 4 reads in both forward and reverse orientation, 4 reads calling the allele with a phred score of ≥20, and 75% allele frequency. After exclusion of multiple consecutive variant calls (in a 12 bp window), variants in drug resistance associated genes or repetitive regions, the remaining positions that had a clear base call for all strains and matched the above mentioned threshold levels in at least 95% of all strains were considered as valid, and combined in a concatenated sequence alignment. Mutations in drug resistance associated genes were analyzed separately but considering the same thresholds, as mentioned above.

**Maximum Likelihood (ML) Phylogenetic Reconstruction and Molecular Clusters**

A ML tree was calculated, based on the concatenated sequence alignment using FastTree (5) with a general time reversible (GTR) substitution model and 1,000 resamples. A molecular cluster was defined as ≥2 strains within a maximum genome wide distance of 5 single nucleotide polymorphisms (SNPs). In case another strain exceeded this threshold but shared a common ancestor with other clustered isolates; we indicated this in Figure 1 and in Appendix 2 but did not considered these few cases for the cluster rates.

**Comparison of Bacterial Demographic and Molecular Clock Models**

For a temporal calibration of phylogenetic trees, we used BEAST 2.4.2 (6) and a concatenated sequence alignment of 6,512 SNPs discriminating all isolates.

Prior to model comparisons within the Bayesian statistical framework, we sought for a proper substitution model using jmodeltest 2.1 (based on maximum-likelihood estimates) (7).
Akaike and Bayesian information criteria (AIC and BIC) were considered for the identification of appropriate substitution models (Appendix 1 Table 2).

To compare a strict versus a relaxed clock model (assuming a constant population size), and different demographic models under the best clock model, we ran each analysis with 300 million steps, sampled 5,000 trees, and discarded 10% as burn-in, resulting in ESS values for all parameters in the hundreds and thousands. Marginal likelihood estimates for each run were computed using path sampling (included in the BEAST 2.4.2 MODEL_SELECTION package) with an $\alpha$ of 0.3 and 50% burn-in with 10 million iterations resulting in ESS values in the hundreds. For model selection, we compared respective marginal likelihood estimates from 50 steps (Appendix 1 Table 3).

**Discrete Phylogeographical Analysis**

The spatial and temporal expansion of MTBC strains belonging to the TUR genotype, i.e., MTBC lineage 4.2.2, (classification inferred from Coll et al. (8), and Niemann et al. (9) was analyzed with BEAST 2.4.2 and the Geo_Sphere package, as described previously (10). For a discrete trait phylogeography analysis we used the likely place of infection for each patient to calculate location annotated time-scaled phylogenies. We used a coalescent constant size demographic model under a strict molecular clock fixed to $10^{-7}$ substitutions per site per year with a GTR substitution model without invariant sites and no gamma distribution, as well as a tip dating approach (best model for TUR genotype dataset, see below, Appendix 1 Table 3). A Chain length of 300 million ignoring a burn-in of 10%, 5,000 trees sampled, resulted in ESS values for all parameters in the thousands. The temporal and geographic distribution was visualized with SPREAD (11) using Google Earth for location mapping of internal nodes and inferred location changes on the basis of a maximum clade credibility (MCC) tree.

**Rationales for Determination of Likely Place of Infection**

To identify a possible source/origin for the identified MDR TUR outbreak, i.e., nosocomial transmission versus a possible introduction of a regional- or community-acquired MDR strain type, we compared 2 hypotheses (1). One was of a fast TB progression, assuming that all patients receiving an MDR TB diagnosis at the national center for treatment of all psychiatric patients with concomitant respiratory illnesses Bela Crkva (BC Hospital) have been infected in BC Hospital itself when there was >1 month between admission and diagnosis. If the
Diagnosis was within the first month following admission at the BC Hospital, the initial hospital or the hometown of the patient was assumed as a likely place of infection (2). The second hypothesis we used was a slow TB progression hypothesis: when MDR TB was diagnosed within the first 2 years after the admission to BC Hospital, we assumed that a patient had been infected elsewhere and was transferred as a latent TB case. The diagnosis after 2 years was considered as a healthcare-associated infection in BC Hospital. The geographic inference of place of infection for both hypotheses was used in the discrete phylogeographic analysis, and marginal likelihoods, inferred by path sampling, were compared as described above.

**Statistical Analysis**

Categorical data were compared by Pearson's $\chi^2$ test, $\chi^2$ test for trend, and Mann-Whitney U test (or Fisher exact test and Monte Carlo simulation when expected group sizes were less than five). All tests were performed as two-sided tests; p values $<$0.05 were considered statistically significant. We performed statistical analyses with SPSS version 20 (IBM, https://www.ibm.com/analytics/spss-statistics-software).

**Ethics**

The study protocol was reviewed and approved by the Ethical Committee, Faculty of Medicine, University of Belgrade, decision number 29/V-14.

**DST Results**

Phenotypic drug resistance rates, other than those for RIF and INH, among 110 MDR-MTBC isolates were as follows: 75.5% (83/110) were resistant to streptomycin (SM), 65.5% (72/110) to ethambutol (EMB), 51.8% (57/110) to pyrazinamide, 17.3% (19/110) to ofloxacin, 14.5% (16/110) to amikacin, and 15.5% (17/110) to capreomycin. Resistance to ethionamide was identified in 21/83 of the isolates (25.3%, 27 DST results were not available), 3/110 (2.7%) were tested resistant to para-aminosalicylic acid, while all isolates were susceptible to cycloserine.

**References**

1. Pardini M, Iona E, Varaine F, Karakozian H, Arzumanian H, Brunori L, et al.; LONG-DRUG Study Group. *Mycobacterium tuberculosis* drug resistance, Abkhazia. *Emerg Infect Dis*. 2005;11:501–3. PubMed [http://dx.doi.org/10.3201/eid1103.040903](http://dx.doi.org/10.3201/eid1103.040903)
2. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–60. PubMed http://dx.doi.org/10.1093/bioinformatics/btp324

3. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303. PubMed http://dx.doi.org/10.1101/gr.107524.110

4. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–9. PubMed http://dx.doi.org/10.1093/bioinformatics/btp352

5. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490. PubMed http://dx.doi.org/10.1371/journal.pone.0009490

6. Bouckaert R, Heled J, Kühnert D, Vaughan T, Wu CH, Xie D, et al. BEAST 2: a software platform for Bayesian evolutionary analysis. PLOS Comput Biol. 2014;10:e1003537. PubMed http://dx.doi.org/10.1371/journal.pcbi.1003537

7. Darriba D, Taboada GL, Doallo R, Posada D. jModelTest 2: more models, new heuristics and parallel computing. Nat Methods. 2012;9:772. PubMed http://dx.doi.org/10.1038/nmeth.2109

8. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812. PubMed http://dx.doi.org/10.1038/ncomms5812

9. Niemann S, Merker M, Kohl T, Supply P. Impact of genetic diversity on the biology of Mycobacterium tuberculosis complex strains. Microbiol Spectr. 2016;4:TBTB2–0022–2016.

10. Lemey P, Rambaut A, Drummond AJ, Suchard MA. Bayesian phylogeography finds its roots. PLOS Comput Biol. 2009;5:e1000520. PubMed http://dx.doi.org/10.1371/journal.pcbi.1000520

11. Bielejec F, Rambaut A, Suchard MA, Lemey P. SPREAD: spatial phylogenetic reconstruction of evolutionary dynamics. Bioinformatics. 2011;27:2910–2. PubMed http://dx.doi.org/10.1093/bioinformatics/btr481
## Appendix 1 Table 1. Resistance profiles of 110 MDR MTBC strains in a longitudinal outbreak, Serbia*

| Resistance to | Phenotypic resistance profile | No. isolates |
|---------------|------------------------------|--------------|
| 2 drugs       | INH, RIF                     | 15           |
| 3 drugs       | SM, INH, RIF                 | 4            |
|               | INH, RIF, EMB                | 4            |
|               | INH, RIF, PZA                | 1            |
| 4 drugs       | SM, INH, RIF, EMB            | 15           |
|               | SM, INH, RIF, PZA            | 5            |
|               | INH, RIF, EMB, PZA           | 4            |
|               | SM, INH, RIF, ETH            | 1            |
| 5 drugs       | SM, INH, RIF, EMB, PZA       | 19           |
|               | SM, INH, RIF, PZA, ETH       | 10           |
|               | SM, INH, RIF, EMB, OFL       | 4            |
|               | SM, INH, RIF, EMB, PAS       | 1            |
|               | SM, INH, RIF, EMB, ETH       | 1            |
|               | INH, RIF, EMB, PZA, ETH      | 1            |
|               | INH, RIF, PZA, AMK, CM       | 1            |
|               | SM, INH, RIF, OFL, CM        | 1            |
| 6 drugs       | SM, INH, RIF, EMB, PZA, ETH  | 2            |
|               | SM, INH, RIF, EMB, AMK, CM   | 2            |
|               | SM, INH, RIF, EMB, PZA, OFL  | 2            |
|               | SM, INH, RIF, EMB, ETH, OFL  | 1            |
|               | SM, INH, RIF, EMB, PZA, PAS  | 1            |
|               | INH, RIF, EMB, OFL, AMK, CM  | 1            |
| 7 drugs       | SM, INH, RIF, EMB, ETH, AMK, CM | 1        |
|               | SM, INH, RIF, EMB, OFL, AMK, CM | 2        |
|               | SM, INH, RIF, EMB, PZA, ETH, OFL | 1    |
| 8 drugs       | SM, INH, RIF, EMB, PZA, OFL, AMK, CM | 6   |
|               | SM, INH, RIF, EMB, PZA, ETH, AMK, CM | 2   |
| 9 drugs       | SM, INH, RIF, EMB, PZA, ETH, OFL, AMK, CM | 1 |

*Resistance profiles of XDR MTBC strains (n = 11). AMK, amikacin; CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MDR, multidrug-resistant; MTBC, *Mycobacterium tuberculosis* complex; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RIF, rifampin; SM, streptomycin; XDR, extensively drug-resistant.
Appendix T

**Table 2.** Likelihood scores for the top 10 substitution models for MDR TB in a longitudinal study, Serbia*

| Substitution model | -lnL       | AIC        | Δ AIC (AIC ranking) | BIC        | Δ BIC (BIC ranking) |
|--------------------|------------|------------|---------------------|------------|---------------------|
| **All isolates**   |            |            |                     |            |                     |
| GTR                | 46521.4    | 93466.8    | 0.0 (1)             | 94904.4    | 0.0 (1)             |
| GTR+I              | 46521.5    | 93469.0    | 2.2 (2)             | 94913.4    | 9.0 (2)             |
| GTR+G              | 46547.9    | 93521.8    | 55.0 (3)            | 94966.2    | 61.8 (5)            |
| TPM1uf             | 46553.7    | 93525.4    | 58.7 (4)            | 94942.7    | 38.3 (3)            |
| GTR+I+G            | 46548.7    | 93525.4    | 58.7 (5)            | 94976.7    | 72.3 (6)            |
| TPM1uf+I           | 46554.2    | 93528.5    | 61.7 (6)            | 94952.6    | 48.1 (4)            |
| TPM1uf+G           | 46577.8    | 93575.5    | 108.8 (7)           | 94999.6    | 95.2 (7)            |
| TPM1uf+I+G         | 46581.1    | 93584.1    | 117.3 (8)           | 95015.0    | 110.6 (8)           |
| HKY                | 46652.6    | 93721.2    | 254.5 (9)           | 95131.8    | 227.3 (9)           |
| TrN                | 46652.1    | 93722.1    | 255.4 (10)          | 95139.5    | 235.0 (10)          |
| **TUR genotype**   |            |            |                     |            |                     |
| TPM1uf             | 10101.0    | 20356.0    | 0.0 (1)             | 20878.2    | 0.0 (1)             |
| TPM1uf+I           | 10100.4    | 20356.8    | 0.8 (2)             | 20885.8    | 7.6 (3)             |
| GTR                | 10098.6    | 20357.2    | 1.1 (3)             | 20899.7    | 21.5 (12)           |
| TPM1uf+I+G         | 10100.8    | 20359.0    | 3.0 (4)             | 20894.7    | 16.5 (8)            |
| GTR+I              | 10098.8    | 20359.5    | 2.8 (5)             | 20908.1    | 29.9 (15)           |
| GTR+I+G            | 10100.8    | 20360.1    | 4.0 (6)             | 20916.1    | 37.9 (16)           |
| HKY                | 10106.7    | 20363.4    | 9.3 (7)             | 20980.8    | 2.5 (8)             |
| HKY+G              | 10106.1    | 20366.2    | 10.1 (8)            | 20888.4    | 10.2 (5)            |

*Models were calculated with jmodeltest 2.1 and statistical model selection based on Akaike and Bayesian information criteria. The best model is assumed to have the lowest criteria value. Boldface indicates substitution models used for Bayesian inference. AIC, Akaike information criteria; BIC, Bayesian information criteria; -lnL, log-likelihood value. Adapted from Posada D. jModelTest: phylogenetic model averaging. MolBiolEvol. 2008;25:1253–56.

---

**Appendix Table 3.** Path sampling results and model selection relative to the best substitution models in a longitudinal study of MDR TB, Serbia*

| Dataset                  | Substitution model | Clock model                  | Demographic model | Marginal L estimate | Δ marginal L estimate | Substitution rate × 10^−7 (SD) |
|--------------------------|--------------------|------------------------------|-------------------|---------------------|-----------------------|-------------------------------|
| GTR model selected as    |                    |                              |                   |                     |                       |                               |
| best substitution model  |                    |                              |                   |                     |                       |                               |
| TUR genotype             | HKY                | Strict (no tip dating)       | Coalescent constant size | -10173.12          | 11.14                 | 1.0 (fixed)                   |
| TUR genotype             | GTR                | Strict (no tip dating)       | Coalescent constant size | -10161.98          | ref                   | 1.0 (fixed)                   |
| TUR genotype             | HKY                | Strict (tip dating)          | Coalescent constant size | -10171.63          | 11.05                 | 1.0 (fixed)                   |
| TUR genotype             | GTR                | Strict (tip dating)          | Coalescent constant size | -10160.58          | ref                   | 1.0 (fixed)                   |
| TUR genotype             | HKY                | Relaxed, lognormal          | Coalescent constant size | -10173.51          | 11.09                 | 0.91 (0.62–1.21)              |
| TUR genotype             | GTR                | Relaxed, lognormal          | Coalescent constant size | -10162.42          | ref                   | 0.92 (0.62–1.21)              |

Strict clock with tip dating under coalescent constant population size selected as best demographic model

| Dataset                  | Substitution model | Clock model                  | Demographic model | Marginal L estimate | Δ marginal L estimate | Substitution rate × 10^−7 (SD) |
|--------------------------|--------------------|------------------------------|-------------------|---------------------|-----------------------|-------------------------------|
| TUR genotype             | GTR                | Strict (no tip dating)       | Coalescent constant size | -10161.98          | 1.40                  | 1.0 (fixed)                   |
| TUR genotype             | GTR                | Strict (tip dating)          | Coalescent constant size | -10160.58          | ref                   | 1.0 (fixed)                   |
| TUR genotype             | GTR                | Relaxed, lognormal          | Coalescent constant size | -10162.42          | 1.84                  | 0.92 (0.62–1.21)              |

Likely city of infection inferred from a fast TB progression assumption selected for a discrete phylogeographical analysis of TUR genotype MDR strains

| Dataset                  | Substitution model | Clock model                  | Demographic model | Marginal L estimate | Δ marginal L estimate | Substitution rate × 10^−7 (SD) |
|--------------------------|--------------------|------------------------------|-------------------|---------------------|-----------------------|-------------------------------|
| TUR genotype (city of   | GTR                | Strict (tip dating)          | Coalescent constant size | -10219.54          | ref                   | 1.0 (fixed)                   |
| infection–fast TB        |                    |                              |                   |                     |                       |                               |
| progression)             |                    |                              |                   |                     |                       |                               |
| TUR genotype (city of   | GTR                | Strict (tip dating)          | Coalescent constant size | -10263.76          | 44.22                 | 1.0 (fixed)                   |
| infection – slow TB      |                    |                              |                   |                     |                       |                               |
| progression)             |                    |                              |                   |                     |                       |                               |

*Sampling results and model selection were determined from the change in marginal L estimates analyzing 50 path sampling steps and chain lengths of 10 million. Boldface indicates estimates relative to the best model. Adapted from Posada D. jModelTest: phylogenetic model averaging. MolBiolEvol 2008;25: 1253–56. TB, tuberculosis; MDR, multidrug-resistant.
## Appendix Table 4. Comparison of demographic, clinical, epidemiologic, and laboratory characteristics of clustered patients with those of nonclustered patients in a longitudinal MDR TB study, Serbia

| Characteristic                        | Whole-genome sequence cluster | p value |
|---------------------------------------|-------------------------------|---------|
|                                       | Yes                           | No      |         |
| Sex                                   |                               |         |         |
| M                                     | 52 (64.2%)                    | 29 (35.8%) | 0.226  |
| F                                     | 11 (50.0%)                    | 11 (50.0%) |         |
| Age group                             |                               |         |         |
| 15–24                                 | 7 (87.5%)                     | 1 (12.5%) | 0.603   |
| 25–34                                 | 2 (28.6%)                     | 5 (71.4%) |         |
| 35–44                                 | 16 (72.7%)                    | 6 (27.3%) |         |
| 45–54                                 | 13 (50.0%)                    | 13 (50.0%) |         |
| 55–64                                 | 18 (66.7%)                    | 9 (33.3%) |         |
| 65+                                   | 7 (53.8%)                     | 6 (46.2%) |         |
| Refugee status                        |                               |         |         |
| Yes                                   | 4 (100.0%)                    | 0 (0.0%) | 0.155   |
| No                                    | 59 (59.6%)                    | 40 (40.4%) |         |
| Region                                |                               |         |         |
| Belgrade                              | 19 (65.5%)                    | 10 (34.5%) | 0.280   |
| Vojvodina                             | 8 (44.4%)                     | 10 (55.6%) |         |
| Central Serbia                        | 34 (64.2%)                    | 19 (35.8%) |         |
| Bosnia and Herzegovina                | 2                             | 1       |         |
| Previous tuberculosis treatment       |                               |         |         |
| Yes                                   | 32 (57.1%)                    | 24 (42.9%) | 0.361   |
| No                                    | 31 (66.0%)                    | 16 (34.0%) |         |
| Alcoholism                            |                               |         |         |
| Yes                                   | 6 (42.9%)                     | 8 (57.1%) | 0.131   |
| No                                    | 57 (64.0%)                    | 32 (36.0%) |         |
| Diabetes mellitus                     |                               |         |         |
| Yes                                   | 3 (37.5%)                     | 5 (62.5%) | 0.256   |
| No                                    | 60 (63.2%)                    | 35 (33.8%) |         |
| Schizophrenia                         |                               |         |         |
| Yes                                   | 23 (92.0%)                    | 2 (8.0%) | <0.001  |
| No                                    | 40 (51.3%)                    | 38 (48.7%) |         |
| Cardiovascular disease                |                               |         |         |
| Yes                                   | 4 (80.0%)                     | 1 (20.0%) | 0.646   |
| No                                    | 59 (60.2%)                    | 39 (39.8%) |         |
| Chronic obstructive respiratory disease|                              |         |         |
| Yes                                   | 6 (60.0%)                     | 4 (40.0%) | 1.000   |
| No                                    | 57 (61.3%)                    | 36 (38.7%) |         |
| Microscopy                            |                               |         |         |
| Positive                              | 42 (55.3%)                    | 34 (44.7%) | 0.051   |
| Negative                              | 20 (76.9%)                    | 6 (23.1%) |         |
| Unknown                               | 1                             |         |         |
| Hospitalization                       |                               |         |         |
| Bela Crkva*†                          |                               |         |         |
| Yes                                   | 26 (92.9%)                    | 2 (7.1%) | <0.001  |
| No                                    | 30 (41.7%)                    | 42 (58.3%) |         |
| Ozren*‡                               |                               |         |         |
| Yes                                   | 30 (45.5%)                    | 36 (54.5%) | <0.001  |
| No                                    | 28 (82.4%)                    | 6 (17.6%) |         |
| Unknown                               | 4                             | 1       |         |
| Cavern presence                       |                               |         |         |
| Yes                                   | 41 (56.9%)                    | 31 (43.1%) | 0.347   |
| No                                    | 15 (68.2%)                    | 7 (31.8%) |         |
| Unknown                               | 7                             | 2       |         |

*Two patients with clustered MDR-MTBC isolates were hospitalized both in Bela Crkva and Ozren.
†Hospital for treatment of all psychiatric patients with concomitant respiratory illnesses in Serbia;
‡Hospital for the initial treatment phase of all patients diagnosed with tuberculosis and multidrug-resistant tuberculosis in Serbia.
Appendix 1 Figure 1. Household and social links within WGS predicted molecular clusters. Genetic distances are based on maximum parsimony analysis. Each circle represents a node of patients who were infected with genetically identical isolates. SNP distances are annotated on branches. Known epidemiologic links between patients are color coded. WGS, whole genome sequencing; SNP, single nucleotide polymorphism.
Appendix 1 Figure 2. Temporal acquisition of resistance to rifampin (mediated by $rpoB$ mutations) among 37 lineage 4.2.2.1 (TUR-genotype) MDR MTBC isolates from Serbia. Time-scaled phylogeny (maximum clade credibility tree) derived from a Bayesian coalescent constant size model of 37 lineage 4.2.2.1 (TUR-genotype) MDR MTBC isolates. The analysis used a GTR substitution model, a strict molecular clock fixed to $1 \times 10^{-7}$ substitutions per site per year, and tip dating (best model according to path sampling analysis, Appendix 1 Table 3). Rifampicin resistance was acquired at least twice. Within the Serbian TUR-outbreak strain the upper clade shares $rpoB$ S450W (orange), the lower clade shares $rpoB$ S450L. Most recent common ancestors of both clades (with a minimum posterior node support of 0.5) were dated to 1998 (95% HPD 1993–2001) and 2003 (95% HPD 2000–2005). Values are rounded to full years. Putative compensatory mutations (in $rpoC$ and $rpoA$) and other resistance mediating mutations identified among TUR-strains are color coded. Internal node support, i.e. posterior density, for all strains (including B109–13) with $rpoB$ S450W, $rpoA$ P25R (both in orange) is 0.37. GTR, general time reversible; HPD, highest posterior density; MDR, multidrug-resistant; MTBC, *Mycobacterium tuberculosis* complex.
Appendix 1 Figure 3. Hypothetical origin of MTBC TUR-genotype outbreak strains assuming a slow TB progression of infected patients. Location annotated time-scaled phylogeny (maximum clade credibility tree) is derived from a Bayesian discrete trait phylogeographical analysis of 37 lineage 4.2.2.1 (TUR-genotype) MDR MTBC isolates. Branches are color coded by the most likely place of infection, assuming a slow TB progression hypothesis (patients diagnosed in the hospital for treatment of psychiatric inpatients with concomitant respiratory illnesses, Bela Crkva Hospital, within the first 2 years after admission were assumed to be infected in the initial hospital or their hometown, and administered as latent TB case). Branches are annotated with probable locations. The origin of the TUR-outbreak strain, applying a slow disease progression hypothesis, is ambiguous, with 7% location support for the most recent common ancestor originating from Belgrade (other location probabilities rank lower). MDR, multidrug-resistant; MTBC, *Mycobacterium tuberculosis* complex; TB, tuberculosis.
Appendix 1 Figure 4. Coexistence of 2 MDR MTBC transmission chains in the psychiatric hospital Bela Crkva, Eastern Serbia. The figure shows all \( n = 26 \) Bela Crkva Hospital patients infected with lineage 4.2.2/TUR genotype MDR MTBC strains. Bars represent hospitalization time; MDR denotes the year of MDR TB diagnosis. The 2 MTBC strain types shown in orange (\( \textit{rpoB S450W} \)) and blue (\( \textit{rpoB S450L} \)) carry individual rifampin resistance–mediating mutations. Gray indicates \( \textit{rpoB H445Y} \). ID, identity number; MDR, multidrug-resistant; MTBC, \textit{Mycobacterium tuberculosis} complex; Pat, patient; TB, tuberculosis.